Dexmethylphenidate Versus Methylphenidate Potency
Dexmethylphenidate (Focalin) is considered approximately twice as potent as racemic methylphenidate on a milligram-for-milligram basis. [1][2]
Mechanism Linking Enantiomer Activity to Dose Conversion
Dexmethylphenidate represents the pharmacologically active d-enantiomer of racemic methylphenidate. [1][2]
FDA-Label Dose Equivalency to Racemic Methylphenidate
Dexmethylphenidate hydrochloride extended-release labeling specifies that, for patients currently using methylphenidate, the recommended starting dose of dexmethylphenidate hydrochloride extended-release is half (1/2) the total daily dose of racemic methylphenidate. [2]
In Vitro Potency Comparison
A U.S. FDA clinical review documents that dexmethylphenidate is in vitro twice as potent as methylphenidate. [1]
Practical Interpretation for Milligram-for-Milligram Use
Milligram-for-milligram substitution between dexmethylphenidate and methylphenidate products is not expected to be equivalent because labeling-supported starting dosing uses a 1:2 dexmethylphenidate-to-racemic-methylphenidate relationship. [1][2]
Medication-Formulation Caveat
Conversion guidance in labeling applies between dexmethylphenidate and racemic methylphenidate exposures for dosing purposes and does not establish identical clinical effect across different extended-release delivery systems. [2]
Initiation and Titration Approach
Dose conversion is typically handled by using labeled starting-dose relationships and subsequent titration by clinical response rather than direct milligram-for-milligram substitution. [2]